Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DR6BU1
|
|||
| Drug Name |
Vaborbactam
|
|||
| Synonyms |
RPX-7009; 1360457-46-0; RPX7009; UNII-1C75676F8V; 2-((3R,6S)-2-hydroxy-3-(2-(thiophen-2-yl)acetamido)-1,2-oxaborinan-6-yl)acetic acid; CHEMBL3317857; 1C75676F8V; 2-[(3R,6S)-2-hydroxy-3-[(2-thiophen-2-ylacetyl)amino]oxaborinan-6-yl]acetic acid; Vaborbactam [INN]; RPX 7009; Vaborbactam. RPX7009; Vaborbactam (USAN/INN); Vaborbactam [USAN:INN]; SCHEMBL620289; GTPL10871; Vabomere (vaborbactam + meropenem); EX-A2589; BDBM50089084; MFCD28502176; AKOS032961376; CS-6445; DB12107; SB17184; 1,2-Oxaborinane-6-acetic acid, 2-hydroxy-3-((2-(2-thienyl)acetyl)amino)-, (3R,6S)-; compound 9f [PMID: 25782055]; NCGC00510003-01; HY-19930; 2-hydroxy-3-((2-(2-thienyl)acetyl)amino)-; D10998; Q27252228; {(3R,6S)-2-hydroxy-3-[(thiophen-2-ylacetyl)amino]-1,2-oxaborinan-6-yl}acetic acid; 2-((3R,6S)-2-hydroxy-3-(2-(thiophen-2-yl)acetamido)-1,2-oxaborinan-6-yl)acetic acid; 2-[(3R,6S)-2-hydroxy-3-[(2-thiophen-2-ylacetyl)amino]oxaborinan-6-yl]acetic acid; 1,2-Oxaborinane-6-acetic acid
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Urinary tract infection [ICD-11: GC08; ICD-10: N39, N39.0] | Phase 3 | [1] | |
| Structure |
 |
Download2D MOL
|
||
| Formula |
C12H16BNO5S
|
|||
| Canonical SMILES |
B1(C(CCC(O1)CC(=O)O)NC(=O)CC2=CC=CS2)O
|
|||
| InChI |
1S/C12H16BNO5S/c15-11(7-9-2-1-5-20-9)14-10-4-3-8(6-12(16)17)19-13(10)18/h1-2,5,8,10,18H,3-4,6-7H2,(H,14,15)(H,16,17)/t8-,10-/m0/s1
|
|||
| InChIKey |
IOOWNWLVCOUUEX-WPRPVWTQSA-N
|
|||
| CAS Number |
CAS 1360457-46-0
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Staphylococcus Beta-lactamase (Stap-coc blaZ) | Target Info | Inhibitor | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT02166476) Efficacy/Safety of Meropenem-Vaborbactam Compared to Piperacillin-Tazobactam in Adults With cUTI and AP. U.S. National Institutes of Health. | |||
| REF 2 | Vaborbactam: Spectrum of Beta-Lactamase Inhibition and Impact of Resistance Mechanisms on Activity in Enterobacteriaceae. Antimicrob Agents Chemother. 2017 Oct 24;61(11):e01443-17. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.